GlassScriptPhysician profile
Chun Wah Ho
NPI 1083699839
$3,098.25
in general payments reported to CMS, 2019-2025
26 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.00 · 2022: $158 · 2023: $695 · 2024: $1,077 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,922.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.09 | 2022-2025 | |
| Amgen INC. | $461.89 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $323.69 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $291.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.81 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $160.56 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $140.60 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $95.49 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $84.96 | 2022-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $82.05 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.14 | 2023-2025 | Xifaxan, Trulance |
| Viatris Specialty LLC | $78.66 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $67.61 | 2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.75 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $60.50 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $51.91 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $47.07 | 2022-2023 | |
| Almatica Pharma LLC | $44.00 | 2023 | Loreev Xr, Sertraline Hcl |
| Aimmune Therapeutics, INC. | $32.37 | 2024-2025 | Zenpep |
| Sumitomo Pharma America, INC. | $23.76 | 2025 | Gemtesa |
| Evoke Pharma, INC. | $22.46 | 2025 | |
| Insulet Corporation | $21.96 | 2024 | Omnipod |
| Janssen Biotech, INC. | $18.37 | 2023 | Stelara |
| Eisai INC. | $17.85 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $17.82 | 2025 | Austedo Xr |
| Smith+Nephew, INC. | $14.05 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Wah Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.